Post-stroke cognitive impairment and the possibility of treatment with cellex

Close metadata

Recommended articles:

The relationship between the development of post-stroke cognitive impairment and changes in the coagulation component of hemostasis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):23-29

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66

Efficacy of Mexidol in combination with cerebral revascularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74

Identifying the neurostimulation target for treatment of cognitive impairment in aging and early cerebral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):34-41

Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):57-62

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Objective. To present neuropsychological characteristics of post-stroke cognitive impairment (PSCI) in acute ischemic stroke (IS) and to assess the efficacy of the drug cellex. Material and methods. A comprehensive neuropsychological testing battery was administered to 288 patients with acute IS. In addition to basic therapy, 30 patients received cellexin the dosage of 0.1 mg (1 ml) subcutaneously for 10 days, treatment was started in the acute phase. Results and сonclusion. Multifunctional PSCI were revealed in 87% of patients with acute IS. Impairments of attention, regulatory functions, speech and memory were identified in the majority of patients. More than a third of patients had multifunctional nonamnestic PSCI. Monofunctionalnonamnestic PSCI were found in 5.5% of patients. Isolated deficit of memory was observed in 2% of patients. PSCI with the predominance of mixed character were found mostly in elderly patients. In the group of young and middle-aged patients,there was a decrease in isolated speed reduction or regulation of cognitive activity, combined cognitive impairment was detected in every fourth patient. There was a trend towards an increase in the age of patients withPSCI of the mixed character. An analysis of the efficacy of cellex in acute IS has shown that the drug improves cognitive status as well as the state of neurodynamic, regulatory and visuospatial functions. Therefore, cellex is effective in treatment of PSCI in acute IS.

Keywords:

stroke

cognitive impairment

neuropsychology

memory

cellex

Authors:

Kulesh A.A.

Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera

Shestakov V.V.

Permskaia gosudarstvennaia meditsinskaia akademiia

List of references:

Gutiérrez Pérez C, Savborg M, Pahlman U, Påhlman U, Cederfeldt M, Knopp E, Nordlund A, Astrand R, Wallin A, Fröjd K, Wijk H, Tarkowski E. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011;26:622-629. doi: 10.1002/gps.2573.
Looi JCL, Sachdev P. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999;53:670-678. doi: 10.1212/wnl.53.4.670.
Sachdev PS, Chen X, Brodaty H, Thompson C, Altendorf A, Wen W. The determinants and longitudinal course of post-stroke mild cognitive impairment. J Int Neuropsychol Soc. 2009;15:915-923. doi: 10.1017/S1355617709990579.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42(9):2672-2713. doi: 10.1161/STR.0b013e3182299496.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. doi: 10.1111/j.1365-2796.2004.01388.x.
Levin OS. Diagnostika i lechenie demencii v klinicheskoj praktike: monografija. 1-e izd. M.: MEDpress-inform; 2010;256. (In Russ.).
Cho SJ, Yu KH, Oh MS, Jung S, Lee JH, Koh IS, Bae HJ, Kang Y, Lee BC. Post-stroke memory impairment among patients with vascular mild cognitive impairment. BMC Neurol. 2014;20:14:244. doi: 10.1186/s12883-014-0244-6.
Snaphaan L, de Leeuw F-E. Poststroke memory function in nondemented patients: a systematic review on frequency and neuroimaging correlates. Stroke. 2007;38;198-203. doi: 10.1161/01.str.0000251842.34322.8f.
Kulesh AA, Shestakov VV. Geterogennost' kognitivnyh narushenij v ostrom periode pervogo ishemicheskogo polusharnogo insul'ta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova (Insul't). 2012;112:8(2) 31-34. (In Russ.).
Kulesh AA, Lapaeva TV, Shestakov VV. Hronobiologicheskie osobennosti insul'ta i postinsul'tnyh kognitivnyh narushenij. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;114:11:31-34. (In Russ.).
Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, Chen S, Ho CL, Mok VC. Influence of amyloid-β on cognitive decline after stroke/transient ischemic attack: three-year longitudinal study. Stroke. 2015;46(11):3074-3080. doi: 10.1161/STROKEAHA.115.010449.
Jang YK, Kwon H, Kim YJ, Jung NY, Lee JS, Lee J, Chin J, Im K, Jeon S, Lee JM, Seong JK, Kim JH, Kim S, Choe YS, Lee KH, Kim ST, Kim JS, Lee JH, Na DL, Seo SW, Kim HJ. Early- vs late-onset subcortical vascular cognitive impairment. Neurology. 2016; doi: 10.1212/WNL.0000000000002357.
Jack CR Jr, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 2016;15(1):56-64. doi: 10.1016/S1474-4422(15)00323-3.
Kovalenko AV, Safronova MN. Vlijanie zelleksa na vosstanovlenie kognitivnyh i rechevyh narushenij v ostrom periode insul'ta. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(1):40-44. (In Russ.).

Close metadata